Johnson & Johnson (JNJ) said Friday that its experimental drug, Tremfya, met primary and major secondary endpoints in a phase 3 study for adults with active psoriatic arthritis.

The company said Tremfya reduced signs and symptoms of active psoriatic arthritis and significantly minimized the progression of structural damage, as measured by radiographic progression at 24 weeks, compared to a placebo.

In the phase 3 study, the company said patients treated with Tremfya also showed significantly less structural damage progression, as assessed by the active psoriatic arthritis modified van der Heijde-Sharp score, which measures joint space narrowing and erosion.

The data was consistent with Tremfya's safety profile, with no new safety concerns identified, it added.